Novel HCV Drug Can Double Response Rate (CME/CE)
(MedPage Today) -- An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said.
Novel HCV Drug Can Double Response Rate (CME/CE)
(MedPage Today) — An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com